| Withdrawn | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma NCT04832438 | Actuate Therapeutics Inc. | Phase 2 |
| Not Yet Recruiting | Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid NCT07162480 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unres NCT07522879 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Recruiting | Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study NCT07320508 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Recruiting | A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma NCT06891560 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers NCT06805617 | Glenn J. Hanna | Phase 2 |
| Terminated | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma NCT06322576 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Recruiting | Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma NCT06781567 | HitGen Inc. | Phase 2 |
| Recruiting | Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or NCT06462183 | Rgenta Therapeutics Inc | Phase 1 |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Withdrawn | The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients wit NCT06199453 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Recruiting | Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma NCT06118086 | Remix Therapeutics | Phase 1 / Phase 2 |
| Recruiting | CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC NCT05774899 | Glenn J. Hanna | Phase 1 / Phase 2 |
| Recruiting | A Study of XMT-1660 in Participants With Solid Tumors NCT05377996 | Mersana Therapeutics | Phase 1 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOL NCT04883671 | Dana-Farber Cancer Institute | N/A |
| Active Not Recruiting | AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer NCT04973683 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma NCT05010629 | Glenn J. Hanna | Phase 2 |
| Active Not Recruiting | MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer NCT04895735 | Mayo Clinic | Phase 2 |
| Completed | Understanding the Burden of ACC Through the Eyes of Patients NCT04706845 | Ayala Pharmaceuticals, Inc, | — |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Unknown | Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 NCT04801264 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Active Not Recruiting | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers NCT04209660 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients NCT04291300 | Radboud University Medical Center | Phase 2 |
| Terminated | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRP NCT04249947 | Poseida Therapeutics, Inc. | Phase 1 |
| Terminated | A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoi NCT04119453 | Elevar Therapeutics | Phase 2 |
| Recruiting | Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation NCT04214366 | Heidelberg University | Phase 2 |
| Completed | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma NCT03999684 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies NCT03886831 | Prelude Therapeutics | Phase 1 |
| Completed | A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations NCT03691207 | Ayala Pharmaceuticals, Inc, | Phase 2 |
| Completed | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial NCT03287427 | Peter MacCallum Cancer Centre, Australia | Phase 1 |
| Recruiting | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or NCT03556228 | VM Oncology, LLC | Phase 1 / Phase 2 |
| Terminated | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies NCT03422679 | Cellestia Biotech AG | Phase 1 / Phase 2 |
| Completed | PSMA-PET Imaging for Advanced ACC/SDC NCT03319641 | Radboud University Medical Center | N/A |
| Completed | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma NCT03087019 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma NCT02942693 | Shanghai Proton and Heavy Ion Center | Phase 2 |
| Active Not Recruiting | Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma NCT02780310 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck NCT02775370 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 2 |
| Completed | Surgical Strategy for Head and Neck Adenoid Cystic Cancer NCT06778915 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | — |
| Completed | Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC) NCT02662608 | M.D. Anderson Cancer Center | N/A |
| Completed | Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma NCT02098538 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy NCT01192087 | Heidelberg University | Phase 1 / Phase 2 |
| Completed | Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma NCT01524692 | University of Virginia | Phase 2 |
| Completed | Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma NCT01558661 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Dovitinib in Adenoid Cystic Carcinoma NCT01417143 | Seoul National University Hospital | Phase 2 |
| Unknown | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy NCT01586767 | Massachusetts General Hospital | N/A |
| Completed | Study of RAD001 in Adenoid Cystic Carcinoma NCT01152840 | Seoul National University Hospital | Phase 2 |
| Completed | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head a NCT00581360 | University of Pittsburgh | Phase 2 |
| Completed | A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands NCT00886132 | University Health Network, Toronto | Phase 2 |